Release Date: July 25, 2025
Expiration Date: July 25, 2026
Activity Overview
This educational activity is an archive of the live virtual presentation held on Thursday, June 12, 2025.
For more information about this educational activity, the faculty, and disclosures, please click here.
Target Audience
This educational program is directed toward attendees of the 2025 European Hematology Association (EHA) Congress. These include a global audience of oncologists, hematologist/oncologists, hematologists, and hematopathologists involved in diagnosing and managing patients with newly diagnosed multiple myeloma (NDMM).
Learning Objectives
Upon successful completion of this activity, you should be better prepared to:
- Evaluate efficacy and safety outcomes from recent clinical trials in patients with NDMM
- Individualize therapy for patients with NDMM based on recent evidence and clinical guidelines
- Implement strategies to address treatment-related adverse events in patients with NDMM
- Discuss the role of MRD assessments for guiding therapy in patients with NDMM
Amrita Krishnan, MD
Professor of Hematology/Hematopoietic Cell
Transplantation
Director, Judy and Bernard Briskin Multiple Myeloma Center
City of Hope Cancer Center
Duarte, CA
Meletios Athanasios (Thanos) C. Dimopoulos, MD
Professor and Chairman
Plasma Cell Dyscrasias Unit
Section of Hematology and Medical Oncology
Department of Clinical Therapeutics
School of Medicine
National and Kapodistrian University of Athens
Alexandra Hospital
Athens, Greece
Shaji Kumar, MD
Professor of Medicine
Consultant and Research Chair, Division of Hematology
Department of Internal Medicine
Mayo Clinic
Rochester, MN
Katja Weisel, MD
Deputy Director of the II. Medical Clinic and Polyclinic
Deputy Director of the University Cancer Center Hamburg
(UCCH)
Hamburg, Germany
Faculty, Staff, and Planners’ Disclosures
The staff of Physicians’ Education Resource®, LLC (PER®) have no relevant financial relationships with ineligible companies.
PER mitigated all COI for faculty, staff, and planners prior to the start of this activity.
Off-Label Disclosure and Disclaimer
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER or any company that provided commercial support for this activity.
GET STARTED WITH THIS PROGRAM:
Register now to gain access to this program.
Create AccountAlready Registered? Login Here
